Joincare Pharmaceutical Group Industry Co., Ltd. is a China-based company engaged in the research, development, production, and sale of pharmaceuticals and health care products, both domestically and internationally. Its portfolio includes chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection applications; chemical APIs and intermediates for human and veterinary drugs; and traditional Chinese medicines such as cold medicine anti-viral granules and anti-tumor medicine. The company also offers diagnostic reagents and equipment, including a mycoplasma pneumoniae IgM antibody test and an antinuclear antibody test kit; OTC products such as Taitai and Jingxin oral liquid, Eagle's American ginseng tea, and YikeTie; and biologics including tocilizumab and mouse nerve growth factor injection. Founded in 1992, it is headquartered in Shenzhen, China.
Joincare Subsidiary's Leuprorelin Acetate Microspheres for Injection 11.25mg Approved for Market
Joincare announced that Shanghai Livzon, under its controlling subsidiary Livzon Group, has received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. Leuprorelin acetate microspheres for injection 11.25mg, a three-month dosage form, has been approved for market. The drug is a Category B product in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug List, with indications including premenopausal breast cancer, prostate cancer and central precocious puberty. To date, cumulative R&D investment in the drug is approximately 94.05 million yuan. Domestically, only Shanghai Livzon holds the approval for this dosage form, excluding the originator. In 2025, terminal sales of long-acting GnRHa sustained-release formulations in China were approximately 10.9 billion yuan, of which the three-month dosage form accounted for 27%.
Joincare Pharmaceutical Group's First-Half Revenue and Net Profit Continue to Decline
Joincare Pharmaceutical Group disclosed its 2026 interim report. In the first half of the year, it achieved operating revenue of 6.583 billion yuan, down 16.66 percent year on year, and net profit attributable to shareholders of the listed company of 648 million yuan, down 17.49 percent year on year. The decline in performance mainly stemmed from its controlling subsidiary Livzon Pharmaceutical Group, whose operating revenue was about 5 billion yuan, down 20.28 percent year on year, and net profit attributable to the parent was 932 million yuan, down 27.23 percent year on year. The company's gross margin fell from 62.21 percent in the same period last year to 58.70 percent, and its net margin fell from 22.33 percent to 20.75 percent. Revenue from innovative drugs in the respiratory segment accounted for nearly 35 percent, while sales revenue in the health food segment was 304 million yuan, up 25 percent year on year.
Joincare Pharmaceutical Group first-half net profit 648 million yuan, down 17.49% year on year
Joincare Pharmaceutical Group disclosed its 2026 half-year report. In the first half, it achieved operating revenue of 6.583 billion yuan, down 16.66% year on year. Net profit attributable to shareholders of the listed company was 648 million yuan, down 17.49% year on year. Basic earnings per share were 0.35 yuan. The company said that amid multiple pressures including deepening medical insurance cost control, the regular advancement of national centralized procurement, and the bottom of the active pharmaceutical ingredient industry cycle, operating performance faced phased pressure, but the business structure continued to improve and core competitiveness remained solid.
600380.CG · Capital · Negative First-half net profit down 17.49% and revenue down 16.66% due to medical insurance cost control, centralized procurement, and API industry cycle bottom.
Joincare discloses guarantee balance of 2.069 billion yuan as annual and quarterly reports show declines in both revenue and net profit
Joincare disclosed that as of July 31, 2026, its total guarantee balance stood at 2.069 billion yuan, accounting for 13.63% of its latest audited net assets. This includes 1.842 billion yuan in guarantees for wholly owned and controlled subsidiaries, and 227 million yuan in guarantees for its joint venture Jinguan Electric Power, with no overdue external guarantees. In July 2026, the company and its controlled subsidiary Livzon Pharmaceutical Group signed multiple guarantee contracts with China Merchants Bank, ICBC, and Bank of Communications, involving entities such as Joincare Haibin Pharmaceutical, Jiaozuo Joincare Biological Products, Shenzhen Taitai Pharmaceutical, Xinxiang Haibin Pharmaceutical, Livzon Group Livzon Pharmaceutical Factory, Sichuan Guangda Pharmaceutical, Zhuhai Livzon Pharmaceutical Trading, Livzon Group Ningxia Pharmaceutical, Livzon Group New Beijiang Pharmaceutical, and Jiaozuo Livzon Synthetic Pharmaceutical. Individual guarantee amounts ranged from 30 million yuan to 302 million yuan. The company's 2025 revenue was 15.216 billion yuan, down 2.58% year-on-year, with net profit attributable to shareholders of 1.336 billion yuan, down 3.68% year-on-year, marking the third time in recent years that both revenue and net profit declined. In the first quarter of 2026, revenue was 3.721 billion yuan, down 8.99% year-on-year, and net profit attributable to shareholders was 415 million yuan, down 4.78% year-on-year. As of the close on August 4, the company's stock had fallen nearly 12% for the year.
600380.CG · Capital · Negative Revenue and net profit declined in 2025 and Q1 2026, with stock down nearly 12% for the year.
000513.CS · Capital · Negative As a controlled subsidiary, its parent's financial declines and guarantee disclosures reflect negatively on its performance.
Joincare Subsidiary Obtains Drug Registration Certificate for Banxia Baizhu Tianma Decoction Granules
Joincare announced that its controlled subsidiary, Livzon Group's subsidiary Sichuan Guangda Pharmaceutical, has received a Drug Registration Certificate issued by the National Medical Products Administration, approving the market launch of Banxia Baizhu Tianma Decoction Granules. This drug is a Category 3.1 new traditional Chinese medicine, the company's first approved Category 3.1 new TCM drug, which will further enrich the company's product pipeline. As of the announcement date, the cumulative R&D investment for this drug was approximately 5.01 million yuan.
China